NEOG
NEUTRAL
$9.61
Live
Neogen Corporation · NASDAQ
Target $12.0
(+24.9%)
$4.32
52W Range
$11.43
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 15, 2026
Market cap
$2.09B
P/E
N/A
ROE
-25.6%
Profit margin
-69.9%
Debt/Equity
0.38
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
NEOG presents a stark contrast between a deteriorating income statement and a robust balance sheet. The Piotroski F-Score of 2/9 indicates significant fundamental weakness and poor operational trends, further evidenced by a -69.94% profit margin and declining revenue. However, the company maintains a strong liquidity position with a current ratio of 3.92 and low leverage (Debt/Equity 0.38), and the stock is currently trading at book value (P/B 0.99). While recent price momentum is bullish, the lack of earnings growth suggests this is a speculative turnaround play rather than a value investment.
Key Strengths
Strong liquidity with a current ratio of 3.92
Low leverage with a Debt/Equity ratio of 0.38
Healthy gross margins at 45.21%
Trading at a fair valuation relative to assets (P/B 0.99)
Strong short-term price momentum (+78% 1Y return)
Key Risks
Severe negative profit margins (-69.94%)
Negative revenue growth (-4.40% YoY)
Very weak Piotroski F-Score (2/9) indicating operational decline
Significant earnings collapse (-180% EPS growth)
High forward P/E (32.76) relative to current negative profitability
AI Fair Value Estimate
Based on comprehensive analysis
$10.0
+4.1% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
28
Weak
50
20
30
40
0
AI Verdict
Speculative Turnaround
Key drivers: Strong balance sheet, Poor operational efficiency, Negative growth trends, Asset-based valuation floor
Confidence
85%
Value
50/100
P/B 0.99, Forward P/E 32.76
Positives
- Price/Book ratio of 0.99 suggests the stock is not overvalued relative to assets
Watchpoints
- Forward P/E of 32.76 is expensive for a company with negative current earnings
Future
20/100
Revenue Growth -4.40%, EPS Growth -180%
Positives
- Analyst target price of $12.00 suggests expected recovery
Watchpoints
- Negative YoY revenue growth
- Severe EPS contraction
Past
30/100
5Y Change -79.3%
Positives
- Recent 6-month recovery (+62.6%)
Watchpoints
- Devastating 5-year performance (-79.3%)
Health
40/100
Piotroski F-Score 2/9, Debt/Equity 0.38
Positives
- Excellent current ratio (3.92)
- Low debt levels
Watchpoints
- Piotroski F-Score of 2/9 is a critical warning sign of financial deterioration
Dividend
0/100
Dividend Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$9.61
Analyst Target
$12.0
Upside/Downside
+24.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NEOG and closest competitors.
Updated 2026-04-14
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NEOG
Neogen Corporation
Primary
|
-79.3% | -40.3% | +78.0% | +62.6% | +5.5% | -3.7% |
|
AAPG
Ascentage Pharma Group Internat
Peer
|
+28.4% | +28.4% | +17.7% | -41.4% | -10.7% | -8.5% |
|
AHG
Akso Health Group
Peer
|
+24.4% | +547.7% | +88.2% | +30.8% | +77.3% | +85.2% |
|
AORT
Artivion, Inc.
Peer
|
+72.4% | +236.1% | +40.5% | +37.0% | -8.2% | -0.8% |
|
ADPT
Adaptive Biotechnologies Corporation
Peer
|
-69.3% | +61.8% | +83.7% | +4.4% | -15.7% | -11.4% |
NEO
Neogen Corporation
Primary
5Y
-79.3%
3Y
-40.3%
1Y
+78.0%
6M
+62.6%
1M
+5.5%
1W
-3.7%
AAP
Ascentage Pharma Group Internat
Peer
5Y
+28.4%
3Y
+28.4%
1Y
+17.7%
6M
-41.4%
1M
-10.7%
1W
-8.5%
AHG
Akso Health Group
Peer
5Y
+24.4%
3Y
+547.7%
1Y
+88.2%
6M
+30.8%
1M
+77.3%
1W
+85.2%
AOR
Artivion, Inc.
Peer
5Y
+72.4%
3Y
+236.1%
1Y
+40.5%
6M
+37.0%
1M
-8.2%
1W
-0.8%
ADP
Adaptive Biotechnologies Corporation
Peer
5Y
-69.3%
3Y
+61.8%
1Y
+83.7%
6M
+4.4%
1M
-15.7%
1W
-11.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
32.76
PEG Ratio
N/A
P/B Ratio
0.99
P/S Ratio
2.4
EV/Revenue
3.13
EV/EBITDA
33.56
Market Cap
$2.09B
Profitability
Profit margins and return metrics
Profit Margin
-69.94%
Operating Margin
-1.56%
Gross Margin
45.21%
ROE
-25.57%
ROA
-0.61%
Growth
Revenue and earnings growth rates
Revenue Growth
-4.4%
Earnings Growth
N/A
Q/Q Revenue Growth
-4.43%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.38
Low debt
Current Ratio
3.92
Strong
Quick Ratio
1.97
Excellent
Cash/Share
$0.73
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q1 2026
Revenue
$0.2B
Gross Margin
46.9%
Op. Margin
-1.6%
Net Margin
-8.0%
Total Assets
$3.4B
Liabilities
$1.3B
Equity
$2.1B
Debt/Equity
0.60x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
49%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-07-29
$N/A
2026-04-09
$-0.08
-6.7% surprise
2026-01-08
$0.1
+50.0% surprise
2025-10-09
$0.04
+9.1% surprise
Healthcare Sector Comparison
Comparing NEOG against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-25.57%
This Stock
vs
-101.52%
Sector Avg
-74.8%
(Below Avg)
Profit Margin
-69.94%
This Stock
vs
-12.47%
Sector Avg
+460.9%
(Superior)
Debt to Equity
0.38
This Stock
vs
3.4
Sector Avg
-88.9%
(Less Debt)
Revenue Growth
-4.4%
This Stock
vs
124.21%
Sector Avg
-103.5%
(Slower)
Current Ratio
3.92
This Stock
vs
4.56
Sector Avg
-14.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NEOG
Neogen Corporation
|
NEUTRAL | $2.09B | - | -25.6% | -69.9% | $9.61 | |
|
AAPG
Ascentage Pharma Group Internat
|
BEARISH | $2.09B | - | -159.6% | -296.8% | $22.32 | Compare |
|
AHG
Akso Health Group
|
BEARISH | $2.14B | - | -68.3% | -% | $2.5 | Compare |
|
AORT
Artivion, Inc.
|
BEARISH | $2.04B | - | -2.5% | -2.2% | $43.02 | Compare |
|
ADPT
Adaptive Biotechnologies...
|
BEARISH | $2.03B | - | -27.8% | -21.5% | $13.17 | Compare |
NEOG
Neogen Corporation
NEUTRAL
Mkt Cap
$2.1B
P/E
-
ROE
-25.6%
Price
$9.61
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-17 | NASSIF MIKHEAL | Chief Executive Officer | Purchase | 23 | $252 |
| 2026-02-02 | NASSIF MIKHEAL | Chief Executive Officer | Purchase | 49 | $486 |
| 2026-01-16 | NASSIF MIKHEAL | Chief Executive Officer | Purchase | 137 | $1,279 |
| 2026-01-07 | RANALLI TAMARA A | Officer | Stock Award | 50,813 | $375,000 |
| 2026-01-07 | RANALLI TAMARA A | Officer | Stock Award | 101,626 | $750,000 |
| 2025-12-01 | NAEMURA DAVID HARTMAN | Former | Option Exercise | 12,912 | $77,214 |
| 2025-11-03 | RIGGSBEE RICHARD BRYAN | Chief Financial Officer | Stock Award | 178,855 | $1,124,998 |
| 2025-11-03 | NASSIF MIKHEAL | Chief Executive Officer | Purchase | 177 | $1,106 |
| 2025-10-27 | TOBIN JAMES P | Director | Option Exercise | 1,777 | $11,000 |
| 2025-10-27 | BOEHM WILLIAM T | Director | Option Exercise | 3,553 | $21,567 |
| 2025-10-27 | RODRIGUEZ RAFAEL A | Director | Option Exercise | 1,777 | $11,000 |
| 2025-10-27 | BOREL JAMES C. | Director | Option Exercise | 2,025 | $12,535 |
| 2025-10-27 | BOREL JAMES C. | Director | Option Exercise | 1,777 | $11,000 |
| 2025-10-27 | GREEN RONALD D | Director | Option Exercise | 1,777 | $11,000 |
| 2025-10-27 | ADENT JOHN EDWARD | Former | Option Exercise | 38,759 | $239,918 |
NASSIF MIKHEAL
Chief Executive Officer
2026-02-17
23 shares
·
$252
NASSIF MIKHEAL
Chief Executive Officer
2026-02-02
49 shares
·
$486
NASSIF MIKHEAL
Chief Executive Officer
2026-01-16
137 shares
·
$1,279
RANALLI TAMARA A
Officer
2026-01-07
50,813 shares
·
$375,000
RANALLI TAMARA A
Officer
2026-01-07
101,626 shares
·
$750,000
NAEMURA DAVID HARTMAN
Former
2025-12-01
12,912 shares
·
$77,214
RIGGSBEE RICHARD BRYAN
Chief Financial Officer
2025-11-03
178,855 shares
·
$1,124,998
NASSIF MIKHEAL
Chief Executive Officer
2025-11-03
177 shares
·
$1,106
TOBIN JAMES P
Director
2025-10-27
1,777 shares
·
$11,000
BOEHM WILLIAM T
Director
2025-10-27
3,553 shares
·
$21,567
RODRIGUEZ RAFAEL A
Director
2025-10-27
1,777 shares
·
$11,000
BOREL JAMES C.
Director
2025-10-27
2,025 shares
·
$12,535
BOREL JAMES C.
Director
2025-10-27
1,777 shares
·
$11,000
GREEN RONALD D
Director
2025-10-27
1,777 shares
·
$11,000
ADENT JOHN EDWARD
Former
2025-10-27
38,759 shares
·
$239,918
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
3 analysts
Piper Sandler
2026-01-12
Neutral
Neutral
Guggenheim
2026-01-09
Buy
Buy
CJS Securities
2025-12-10
Market Perform
Market Outperform
Past News Coverage
Recent headlines mentioning NEOG from our newsroom.
Newest → oldest
No matching news yet.